Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy

Por Papaevangelou, E, Almeida, G S, Jamin, Y, Robinson, S P, deSouza, N M
Publicado no Br J Cancer (2015)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function

Por Baker, L C J, Boult, J K R, Walker-Samuel, S, Chung, Y-L, Jamin, Y, Ashcroft, M, Robinson, S P
Publicado em 2012

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography

Por Li, J, Jamin, Y, Boult, J K R, Cummings, C, Waterton, J C, Ulloa, J, Sinkus, R, Bamber, J C, Robinson, S P
Publicado em 2014

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics

Por Boult, J K R, Jamin, Y, Jacobs, V, Gilmour, L D, Walker-Samuel, S, Halliday, J, Elvin, P, Ryan, A J, Waterton, J C, Robinson, S P
Publicado em 2012

Oxygen-enhanced MRI can accurately identify, quantify and map tumour hypoxia in preclinical models

Por O'Connor, JPB, Boult, JKR, Jamin, Y, Babur, M, Finegan, KG, Williams, KJ, Reynolds, AR, Little, RA, Jackson, A, Parker, GJM, Waterton, JC, Robinson, SP
Publicado no Cancer Imaging (2015)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

Por Beloueche-Babari, M, Jamin, Y, Arunan, V, Walker-Samuel, S, Revill, M, Smith, P D, Halliday, J, Waterton, J C, Barjat, H, Workman, P, Leach, M O, Robinson, S P
Publicado em 2013

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

Por Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., El Wakil, A., Witek, B., Jamin, Y., Umapathy, G., Robinson, S. P., Johnson, T. W., Smeal, T., Martinsson, T., Chesler, L., Palmer, R. H., Hallberg, B.
Publicado no Dis Model Mech (2016)